New hope for kids with severe psoriasis: adalimumab trial launches
NCT ID NCT07529925
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug adalimumab in 30 Chinese children aged 4 to 17 with severe plaque psoriasis that hasn't improved with creams or light therapy. The goal is to see if adalimumab can safely reduce skin symptoms like redness and scaling. The main measure is how many children achieve at least a 75% improvement in their psoriasis by week 16.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adalimumab (a drug that blocks inflammation)
- What this could lead to
- If successful, this could provide a safe and effective treatment option for Chinese children with severe plaque psoriasis who haven't responded to other therapies.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to all children. Adalimumab can have side effects like increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE PLAQUE PSORIASIS IN CHINESE CHILDREN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.